Cystic fibrosis prenatal genetic screening for high-risk populations recommended by NIH working groups.
This article was originally published in The Gray Sheet
CYSTIC FIBROSIS PRENATAL GENETIC SCREENING FOR HIGH-RISK GROUPS ONLY is recommended by two National Institutes of Health working groups at an Oct. 15-16 workshop in Bethesda. Summarizing recommendations from the National Human Genome Research Institute-sponsored workshop, University of California at Los Angeles School of Medicine's Nancy Press, PhD, said on Oct. 16 that CF carrier screening should "not be offered to all populations, but rather to populations who are at high risk."
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.